Placebo Response in Pediatric Anxiety Disorders: Implications for Clinical Trial Design and Interpretation
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The characterization and prediction of placebo response in clinical trials of youth with anxiety disorders have received little attention, despite the critical effects of placebo response rate on the success or failure of clinical trials. With this in mind, we sought to examine the factors that predict or influence placebo response in randomized controlled trials of youth with anxiety disorders. METHODS: Prospective, randomized, parallel-group controlled trials of psychopharmacologic interventions in pediatric patients with anxiety disorders were identified using a search of PubMed/Medline (1966-2015). Weighted least squares regression models and z-tests were utilized to examine the impact of continuous and categorical variables, respectively, on placebo response. These variables included demographic (e.g., age, percent white, percent female), clinical (e.g., baseline symptom severity), and trial characteristics (sample size, duration, funding). Finally, the relationship between the class of comparator medication and placebo response rate was examined using a multiple comparison for proportions test. RESULTS: The analyses of data from 14 trials involving 2230 patients and 9 medications reveal that higher placebo response rates were associated with a greater number of study sites (p = 0.013) and fewer patients per site (p < 0.008), while placebo dropout rates increased with more recent publication (p = 0.01) and were positively associated with the number of study visits (p < 0.02). Lower placebo response rates were associated with federally funded studies (z = -4.61, p < 0.001), studies conducted in the United States (z = 1.81, p < 0.035), and with an increased likelihood of detecting a significant effect on the primary outcome (z = 4.58, p < 0.0001). Additionally, studies, in which the majority of patients (>60%) had a diagnosis of social anxiety disorder, exhibited lower placebo response rates (p < 0.001). Finally, for trials, effect size has decreased over time (p = 0.004). CONCLUSIONS: Important trial-specific factors affect placebo response and placebo dropout in youth with anxiety disorders and have pragmatic implications for the conduct and design of clinical trials and raise the possibility that limiting the number of sites while maximizing the number of patients per site could enhance the ability to detect medication-placebo differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Bruce, S. E., Yonkers, K. A., Otto, M. W., Eisen, J. L., Weisberg, R. B., Pagano, M., Shea, M. T., & Keller, M. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1179 · Cited by 963
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
Beesdo, K., Pine, D. S., Lieb, R., & Wittchen, H.-U. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.177 · Cited by 494 · cited 2×
“2005), frequently emerge during adolescence (Beesdo et al. 2010; Wehry et al. 2015), and are associated with significant morbidity and mortality (Sareen et al.”
BackgroundGinsburg, G. S., Kendall, P. C., Sakolsky, D., Compton, S. N., Piacentini, J., Albano, A. M., Walkup, J. T., Sherrill, J., Coffey, K. A., Rynn, M. A., et al. (2011) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0025933 · Cited by 337
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256 · cited 13×
“In the entire sample of patients with MDD, OCD, and non-OCD anxiety disorders, placebo response was negatively associated with Caucasian status and the percentage of male participants, while the presence of a washout decreased placebo response.”
BackgroundResultInfluentialWagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240
Compton, S. N., Peris, T. S., Almirall, D., Birmaher, B., Sherrill, J., Kendall, P. C., March, J. S., Gosch, E. A., Ginsburg, G. S., Rynn, M. A., et al. (2014) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0035458 · Cited by 226
SET-C Versus Fluoxetine in the Treatment of Childhood Social Phobia
BEIDEL, D. C., TURNER, S. M., SALLEE, F. R., AMMERMAN, R. T., CROSBY, L. A., & PATHAK, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318154bb57 · Cited by 223
Imipramine Treatment of Children with Separation Anxiety Disorder
KLEIN, R. G., KOPLEWICZ, H. S., & KANNER, A. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199201000-00005 · Cited by 201
Cited by
Mossman, S. A., Luft, M. J., Schroeder, H. K., Varney, S. T., Fleck, D. E., Barzman, D. H., Gilman, R., DelBello, M. P., & Strawn, J. R. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900404 · Cited by 471
Self-citationLocher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Strawn, J. R., Mills, J. A., Sauley, B. A., & Welge, J. A. (2018) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2018.01.015 · Cited by 98
Self-citationStrawn, J. R., Compton, S. N., Robertson, B., Albano, A. M., Hamdani, M., & Rynn, M. A. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0132 · Cited by 55
Self-citationThe current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna, P. J., Farahdel, E., Potenza, M. N., & Crowley, M. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2199921 · Cited by 3
Metadata
- Authors
- Dobson, E. T., & Strawn, J. R.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-10
- Volume
- 26
- Issue
- 8
- Pages
- 686-693
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2330091287
- Cited by
- 23
- References
- 15
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Placebo Response in Pediatric Anxiety Disorders: Implications for Clinical Trial Design and Interpretation. https://app.cochat.ai/papers/10.1089/cap.2015.0192
- The paper
- Dobson, E. T., & Strawn, J. R. (2016). Placebo Response in Pediatric Anxiety Disorders: Implications for Clinical Trial Design and Interpretation. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2015.0192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.